Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more
Market Cap & Net Worth: Sun Pharma Advanced Research Company Limited (SPARC)
Sun Pharma Advanced Research Company Limited (NSE:SPARC) has a market capitalization of $427.78 Million (₹37.05 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #17442 globally and #801 in its home market, demonstrating a -7.91% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sun Pharma Advanced Research Company Limited's stock price ₹114.16 by its total outstanding shares 324521588 (324.52 Million).
Sun Pharma Advanced Research Company Limited Market Cap History: 2015 to 2026
Sun Pharma Advanced Research Company Limited's market capitalization history from 2015 to 2026. Data shows change from $1.27 Billion to $427.78 Million (-11.03% CAGR).
Index Memberships
Sun Pharma Advanced Research Company Limited is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY 500
NIFTY500
|
$1.33 Trillion | 0.01% | #456 of 500 |
|
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
|
$535.62 Billion | 0.02% | #367 of 400 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$1.39 Trillion | 0.01% | #584 of 750 |
|
NIFTY SMALLCAP 250
NISM250
|
$188.43 Billion | 0.06% | #237 of 250 |
Weight: Sun Pharma Advanced Research Company Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sun Pharma Advanced Research Company Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sun Pharma Advanced Research Company Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.70x
Sun Pharma Advanced Research Company Limited's market cap is 0.70 times its annual revenue
1.01x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.14 Billion | $1.61 Billion | -$699.92 Million | 0.71x | N/A |
| 2017 | $1.90 Billion | $1.81 Billion | -$1.20 Billion | 1.05x | N/A |
| 2018 | $704.66 Million | $782.59 Million | -$1.97 Billion | 0.90x | N/A |
| 2019 | $585.31 Million | $1.83 Billion | -$1.45 Billion | 0.32x | N/A |
| 2020 | $726.02 Million | $768.14 Million | -$3.12 Billion | 0.95x | N/A |
| 2021 | $1.05 Billion | $2.53 Billion | -$1.51 Billion | 0.41x | N/A |
| 2022 | $781.67 Million | $1.37 Billion | -$2.03 Billion | 0.57x | N/A |
| 2023 | $1.07 Billion | $2.39 Billion | -$2.23 Billion | 0.45x | N/A |
| 2024 | $751.50 Million | $755.45 Million | -$3.87 Billion | 0.99x | N/A |
| 2025 | $503.81 Million | $717.70 Million | -$3.43 Billion | 0.70x | N/A |
Competitor Companies of SPARC by Market Capitalization
Companies near Sun Pharma Advanced Research Company Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Sun Pharma Advanced Research Company Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Sun Pharma Advanced Research Company Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Sun Pharma Advanced Research Company Limited's market cap moved from $1.27 Billion to $ 427.78 Million, with a yearly change of -11.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹427.78 Million | -15.09% |
| 2025 | ₹503.81 Million | -32.96% |
| 2024 | ₹751.50 Million | -30.07% |
| 2023 | ₹1.07 Billion | +37.49% |
| 2022 | ₹781.67 Million | -25.31% |
| 2021 | ₹1.05 Billion | +44.15% |
| 2020 | ₹726.02 Million | +24.04% |
| 2019 | ₹585.31 Million | -16.94% |
| 2018 | ₹704.66 Million | -62.96% |
| 2017 | ₹1.90 Billion | +66.57% |
| 2016 | ₹1.14 Billion | -10.29% |
| 2015 | ₹1.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Sun Pharma Advanced Research Company Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $427.78 Million USD |
| MoneyControl | $427.78 Million USD |
| MarketWatch | $427.78 Million USD |
| marketcap.company | $427.78 Million USD |
| Reuters | $427.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.